Literature DB >> 17050003

The human Cx40 promoter polymorphism -44G-->A differentially affects transcriptional regulation by Sp1 and GATA4.

Mehran Firouzi1, Marti F A Bierhuizen, Bart Kok, Birgit E J Teunissen, Anita T Jansen, Habo J Jongsma, W Antoinette Groenewegen.   

Abstract

Expression of the tissue-specific gap junction protein connexin(Cx)40 is regulated by the interaction of ubiquitous and tissue-specific factors such as Sp1 and GATA4. Cardiac Cx40 expression is altered under pathological conditions such as atrial fibrillation. A human promoter polymorphism, a G-->A change at position -44 that has been associated with atrial-specific arrhythmias, is located between the TBE-NKE-Sp and GATA consensus transcription factor binding sites important for the regulation of the mouse Cx40 gene. The presence of the A-allele at position -44 in promoter-reporter constructs significantly reduces promoter activity. Using electrophoretic mobility shift assays and luciferase reporter assays in various cell types, we show that Sp1 and GATA4 are important regulators of human Cx40 gene transcription and that the -44 G-->A polymorphism negatively affects the promoter regulation by the transcription factors Sp1 and GATA4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050003     DOI: 10.1016/j.bbaexp.2006.09.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation.

Authors:  Robert C Wirka; Shamone Gore; David R Van Wagoner; Dan E Arking; Steven A Lubitz; Kathryn L Lunetta; Emelia J Benjamin; Alvaro Alonso; Patrick T Ellinor; John Barnard; Mina K Chung; Jonathan D Smith
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-11-13

Review 2.  The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system.

Authors:  Eliseo A Eugenin; Daniel Basilio; Juan C Sáez; Juan A Orellana; Cedric S Raine; Feliksas Bukauskas; Michael V L Bennett; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-23       Impact factor: 4.147

Review 3.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 4.  Genetic mechanisms of atrial fibrillation: impact on response to treatment.

Authors:  Dawood Darbar; Dan M Roden
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

Review 5.  Gap junctions in the control of vascular function.

Authors:  Xavier F Figueroa; Brian R Duling
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

6.  Connexins and Atrial Fibrillation in Obstructive Sleep Apnea.

Authors:  Abdelnaby Khalyfa; David Gozal
Journal:  Curr Sleep Med Rep       Date:  2018-10-26

Review 7.  Transcriptional factors in calcium mishandling and atrial fibrillation development.

Authors:  Wenli Dai; Sneha Kesaraju; Christopher R Weber
Journal:  Pflugers Arch       Date:  2021-05-18       Impact factor: 4.458

8.  Identification of long non-coding RNAs as novel biomarker and potential therapeutic target for atrial fibrillation in old adults.

Authors:  Yingjia Xu; Ritai Huang; Jianing Gu; Weifeng Jiang
Journal:  Oncotarget       Date:  2016-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.